BELux Children OutcoME During A(@)Dulthood With GHD

BELux Children OutcoME During A(@)Dulthood With Growth Hormone Deficiency

Our objective is to evaluate the outcome in adulthood of Belgian and Luxembourgish patients treated with rhGH during childhood for CO-GHD. The primary goal is to determine the proportion of adult CO-GHD patients who continue to receive regular medical follow-up and those still undergoing rhGH therapy using a questionnaire. Secondary objectives include assessing the regularity of follow-up and compliance with treatment in adulthood, evaluating possible comorbidities, health issues, lifestyle, living environment, and quality of life. Additionally, we aim to assess the metabolic profile in adulthood, particularly focusing on BMI, glycemic, and lipid data, for patients who consent to share their current clinical and biological data. Data will be described according to treatment adherence and CO-GHD etiology/phenotypes (e.g., idiopathic vs. organic GHD, isolated vs. combined GHD, partial vs. severe GHD).

Inclusion Criteria:

• Age > or = 18 years
• Diagnosed with child-hood onset growth hormone deficiency (CO-GHD) (no exclusion criteria: isolated or multiple GHD, idiopathic or organic, severe or partial)
• Registered in the BELGROW registry (informed consent at the time of inclusion in registry)
• Stopped treatment with rhGH for growth after 2011
• Persistent GHD at the end of growth

Exclusion Criteria:

• No exclusion criteria